



## Supplementary Figures




**Figure S1. Recombination rates of *LSL-Kras<sup>+G12D</sup>* allele. A.** Percentage of *LSL-Kras<sup>+G12D</sup>* alleles showing recombination, in tdTomato<sup>+</sup> cells isolated by FACS from pancreata of 3 *Ptf1a-CreER<sup>+/-</sup>; LSL-Kras<sup>+G12D</sup>; LSL-tdTomato<sup>+/-</sup>* mice (dots) 5 days following tamoxifen treatment, as assessed by semi-quantitative PCR conducted on genomic DNA, comparing the ratio of recombined to non-recombined flox alleles. **B.** Representative images (low magnification – top, high magnification – middle and bottom) of PanIN tissues stained with an antibody against tdTomato, showing tdTomato expression in lesion cells and in surrounding acinar cells. Size markers = 50 $\mu$ m.




**Figure S2. PanIN stroma contains senescent fibroblasts.** **A.** Representative FACS analysis of cells from *Ptf1a-CreER<sup>+/+</sup>; LSL-Kras<sup>G12D</sup>* mice 3 months after Kras activation (Kras, right panels) and control *Ptf1a-CreER<sup>+/+</sup>* mice (left panel, Cont). The tdTomato transgene was replaced by staining for the epithelial marker Epcam. Co-staining of Epcam and SA-βGal, conducted using the fluorescent substrate C<sub>12</sub>FDG, allowed the characterization and isolation of Epcam<sup>-</sup> SA-βGal<sup>high</sup> cells, whose numbers were substantially increased in the Kras-expressing mice versus control mice (gate labeled blue). Staining with the cancer-associated fibroblast markers Pdpn and Cd140a (Pdgfra)<sup>43</sup> (right panel) revealed that the majority of Epcam<sup>-</sup> SA-βGal<sup>high</sup> cells are fibroblasts. Percentages on right panel dot plot are of total Pdpn<sup>+</sup>, or of Cd140a<sup>+</sup>, out of Epcam<sup>-</sup> SA-βGal<sup>high</sup> cells. **B.** Percentages of indicated subpopulations out of Epcam<sup>-</sup> SA-βGal<sup>high</sup> cells. The Cd140a<sup>+</sup> fibroblast subpopulation is included in the Pdpn<sup>+</sup> population; the F4/80<sup>+</sup> macrophage subpopulation is included in the Cd45<sup>+</sup> immune population. Values represent mean across individual mice (dots) ± S.E.M. **C.** Expression levels of the *Cdkn2a* senescence marker measured by qRT-PCR in SA-βGal positive and negative subpopulations of Epcam<sup>+</sup> epithelial compartment and Cd140<sup>+</sup> fibroblasts, isolated from Kras activated mice, or in corresponding SA-βGal-negative cells isolated from control mice (Cont). Values indicate average of cells sorted from two mice (dots).

43. Elyada E, Bolisetty M, Laise P, et al. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. *Cancer Discov* 2019;9:1102-23.


A




B




C




**Figure S3. Isolation and profiling of the tdTomato<sup>+</sup> SA-βGal<sup>high</sup> population.** **A.** Sorting procedure for the isolation of senescent and non-senescent PanIN cells, shown on a representative FACS of cells from triple-transgenic *Ptf1a-CreER<sup>+/-</sup>; LSL-Kras<sup>+G12D</sup>; LSL-tdTomato<sup>+/-</sup>* mice 3 months after Kras activation. Following FSC and SSC gating to eliminate cell doublets, cells were gated to exclude CD45<sup>+</sup> (hematopoietic) and CD31<sup>+</sup> (endothelial) fractions; tdTomato<sup>+</sup> SA-βGal<sup>-</sup> cells (red, top left), and tdTomato<sup>+</sup> SA-βGal<sup>high</sup> (green, top right) were gated for isolation as indicated. **B.** Additional gene sets upregulated (left) and downregulated (right) in SA-βGal<sup>+</sup> versus SA-βGal<sup>-</sup> PanIN cells isolated from Kras-activated mice 3 months after tamoxifen treatment. Values indicate  $-\log_{10}$  of Adj *P* value as determined by Ingenuity Pathway Analysis. **C.** Gene set enrichment analysis (GSEA) of expression profiles of SA-βGal<sup>+</sup> versus SA-βGal<sup>-</sup> PanIN cells indicating enrichment for inflammatory (top) and senescent cell (bottom) gene sets.




**Figure S4. scRNA-Seq of Kras-driven PanINs.** **A.** Uniform manifold approximation and projection (Umap) cell clustering of the scRNA-seq expression profile of epithelial cells from *Ptf1a-CreER*<sup>+/-</sup>; *LSL-Kras*<sup>+G12D</sup>; *LSL-tdTomato* mice, as shown in Fig. 2I,J. Colors indicate different time points after Kras activation in which cells were collected, as indicated. Cells from *Ptf1a-CreER*<sup>+/-</sup>; *LSL-tdTomato* control mice (CTRL) are labeled red. Numbers of sequenced cells at each time point are indicated in parentheses. **B.** Expression of tdTomato across cells (red – high, grey - low), observed in normal acinar cells as well as PanIN cells.



**Figure S5. Bcl2-family protein inhibition by ABT-737 does not induce apoptosis in stromal cells.** *Pdx1-Cre<sup>+/-</sup>; LSL-Kras<sup>+G12D</sup>* mice were treated by caerulein at 2.5 months of age, followed by treatment with ABT-737 two weeks subsequently, and analyzed two days later. **A.** Co-staining of pancreas sections from vehicle and ABT-737 treated mice for CC3 (red), and the fibroblast marker vimentin (green), showing no overlap in expression, with CC3 stain detected only within PanIN epithelial ductal structures. **B.** Co-staining of pancreas sections from vehicle and ABT-737 treated mice for CC3 (red), the macrophage marker F4/80 (green) showing no overlap in expression.




**Figure S6. Bcl2-family protein inhibition by ABT-737 increases the percentage of Ki67<sup>+</sup> cells in PanINs.** *Pdx1-Cre<sup>+/-</sup>;LSL-Kras<sup>+G12D</sup>* mice were treated by caerulein at 2.5 months of age, followed by treatment with ABT-737 two weeks subsequently, and analyzed two days later. **A.** Representative images of pancreas sections from vehicle or ABT-737 treated mice stained for Ki67 (brown). **B.** Percentage of Ki67<sup>+</sup> cells in PanINs from same mice. \*,  $P < 0.05$ , \*\*,  $P < 0.005$ , *t*-test.



**Figure S7. Bcl2-family protein inhibition by ABT-737 does not eliminate Dclk1<sup>+</sup> cells.** *Pdx1-Cre<sup>+/-</sup>;LSL-Kras<sup>+G12D</sup>* mice were treated by caerulein at 2.5 months of age, followed by treatment with ABT-737 two weeks subsequently, and analyzed two days later. **A.** Representative staining for Dclk1 in pancreas sections from vehicle and ABT-737 treated mice. **B.** Percentage of Dclk1<sup>+</sup> cells in PanINs from same mice. \*,  $P < 0.05$ , \*\*,  $P < 0.005$ , *t*-test.





**Figure S8. High grade PanINs and pancreatic carcinoma in *Pdx1-Cre*<sup>+/-</sup>;*LSL-Kras*<sup>+G12D</sup> mice.** Representative images of PanIN2 and PanIN3 lesions (panel A) and pancreatic ductal carcinoma (PDAC, panel B) observed in caerulein-treated *Pdx1-Cre*<sup>+/-</sup>;*LSL-Kras*<sup>+G12D</sup> mice at 9 months of age. Lesions are from mice that did not receive ABT-737. Size marker = 200µm.